Ask the Experts

Meet our Expert: Dr. Stuart Mair

Learn more about Dr. Stuart Mair's areas of expertise and ask a question.

Dr. Stuart Mair: Global Vice President, Medical, Early Development

Dr. Stuart Mair: Global Vice President, Medical, Early Development at Quotient Sciences

Dr. Stuart (Stu) Mair has over 16 years experience of delivering exploratory clinical studies in the CRO Industry. He has delivered over 100 First-in-Human (FIH) studies and is an expert in the design and implementation of exploratory clinical trials from First-in-Human to Proof-of-Concept (POC) in patient groups with PD biomarkers. Stuart has advised clients on multiple study types from simple PK, BE and characterisation studies to complex flexible designs with multiple portions delivered under a single protocol.

Prior to joining Quotient Sciences, Dr. Mair was the Medical Director at Charles River Laboratories. Stuart holds a MBChB (Bachelor of Medicine and Bachelor of Surgery) degree and DRCOG, DCPSA, and MFPM credentials from the University of Aberdeen in the UK.


Topics of interest

First-in-Human (FIH) studies, Proof-of-Concept (POC) studies, PK characterisation studies, BE characterisation studies


Connect on LinkedIn

Visit profile


Ask a question

If you have a question for Dr. Stuart Mair, fill out the form below.

Contribution to Publications 

"CC‑99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro‑inflammatory cytokine production"

Spondyloarthritis is a type of inflammatory disease that impacts the vertebral column. It comprises a group of inflammatory rheumatic diseases that is characterized by spinal and peripheral joint oligoarthritis and enthesitis and may be associated with mucocutaneous, ocular, and/or cardiac comorbidities. There is an unmet need when it comes to therapies that can address both disease-related parameters and radiographic progression of spondyloarthritis. 

Dr. Stuart Mair contributed to a peer-reviewed scientific article on Arthritis Research & Therapy with BioMed Central (BMC). The study, led by Bristol Meyers Squibb and its researchers, reviews a phase I clinical trial to assess safety and tolerability of MK2 inhibitor CC-99677, a new treatment for ankylosing spondylitis (AS) and related conditions

Access now

Learn more